Application of asiaticoside in the treatment of abnormal bone metabolism

A technology of asiaticoside and osteoclasts, which is applied in the field of biomedicine to achieve the effect of low dosage
CN108159060BActive Publication Date: 2021-01-26THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
Publication Date
2021-01-26

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses asiaticoside, and a function of a pharmaceutically acceptable derivative thereof in bone metabolic abnormality. The asiaticoside has an adjustment function on simultaneously inhibiting osteoclast formation under the situation of bone metabolic abnormality, is low in effective dosage, and has a better effect on adjusting bone metabolic abnormality. The invention defines an intervention way of an asiaticoside related drug. The invention clarifies that a molecular mechanism in a bone microenvironment and a potential pharmacology intervention way are crucial to identifyinga novel treatment compound.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of biomedicine, in particular to the application of asiaticoside in the treatment of abnormal bone metabolism. Background technique

[0002] Abnormal bone metabolism (Osteoporosis) is a dynamic pathological condition caused by an imbalance between osteoblast bone formation and osteoclast bone resorption. Maintaining the link between osteoclasts and osteoblasts is critical for maintaining bone mass. Once osteoclast-induced bone resorption exceeds osteoblast-induced bone formation, it will progress to osteoporosis. Osteoporosis is primarily characterized by decreased bone mineral and structural disturbances in the skeletal system. Osteoclast and osteoblast differentiation and formation are regulated by several signaling pathways. For the osteoclast system, the receptor activator of NF-κB ligand (RANKL) is a member of the tumor necrosis factor family (TNF) mainly expressed by chondrocytes and osteocytes. RANKL is imp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More